Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors

作者： Brian I Rini , David F McDermott , Michael B Atkins

DOI: 10.1016/S1470-2045(21)00130-3

关键词: Poor risk 、 Kinase 、 Renal cell carcinoma 、 Immune checkpoint inhibitors 、 Cancer research 、 Immune checkpoint 、 Medicine